Neuroendocrine neoplasm

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:877
Who is this for?
Show terms as
12Active trials29Specialists8Treatment centers

Where are you in your journey?

ℹ
UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Nov 2026A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India

Bristol-Myers Squibb — PHASE4

TrialNOT YET RECRUITING
Apr 2026Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Roswell Park Cancer Institute — PHASE2

TrialRECRUITING
Mar 2026Resection of the Primary Tumor vs. Systemic Treatment Alone for Patients With Small Intestinal Neuroendocrine Tumors and Unresectable Metastases: a Europe-wide Study

Insel Gruppe AG, University Hospital Bern

TrialRECRUITING
Dec 2025Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake

Akiva Mintz — PHASE2

TrialRECRUITING
Dec 2025DCEUS to Assess Treatment Response to PRRT in GEP-NET

Fondazione Policlinico Universitario Agostino Gemelli IRCCS — NA

TrialRECRUITING
Aug 2025R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

Rise Therapeutics LLC — PHASE1

TrialRECRUITING
Jun 2025Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies

Xijing Hospital — NA

TrialNOT YET RECRUITING
May 2025Risk Factors for Neuroendocrine Neoplasms

Bavarian Cancer Registry

TrialRECRUITING
May 2025A Trial of MHB088C in Advanced Extrapulmonary Neuroendocrine Cancer

Beijing GoBroad Hospital — PHASE2

TrialNOT YET RECRUITING
Apr 2025NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial

Second Affiliated Hospital, School of Medicine, Zhejiang University — PHASE2

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Neuroendocrine neoplasm.

12 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

12 recruitingView all trials with filters →
Phase 31 trial
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
Phase 3
Actively Recruiting
PI: Jaume Capdevila, M.D. Ph.D. (Hospital Vall d'Hebron) · Sites: Edegem, Edegem; Brussels +25 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Phase 25 trials
NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial
Phase 2
Actively Recruiting
· Sites: Hangzhou, Zhejiang · Age: 18–75 yrs
View on ClinicalTrials.gov ↗I'm interested →
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
Phase 2
Active
PI: Adel Mandl (Yale University Cancer Center LAO) · Sites: Birmingham, Alabama; Tucson, Arizona +44 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
A Study of PM8002 in Combination With Chemotherapy in Patients With NEN
Phase 2
Actively Recruiting
PI: Jianming Xu (Chinese PLA General Hospital) · Sites: Chongqing, Chongqing Municipality; Fuzhou, Fujian +11 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)
Phase 2
Actively Recruiting
· Sites: Naples, Campania · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
Phase 2
Actively Recruiting
PI: Jasmeet Kaur, MD (Roswell Park Cancer Institute) · Sites: Buffalo, New York · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
N/A2 trials
Lateral Pelvic Lymph Node Dissection for Rectal Neuroendocrine Neoplasms Undergoing Laparoscopic Total Mesenteric Excision
N/A
Actively Recruiting
PI: Haitao Zhou (National Cancer Center, China) · Sites: Beijing, Beijing Municipality · Age: 18–75 yrs
View on ClinicalTrials.gov ↗I'm interested →
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
N/A
Actively Recruiting
PI: Laura C Hernández Ramírez, MD, PhD (Universidad Nacional Autonoma de Mexico) · Sites: Mexico City, Mexico City; Mexico City, Mexico City +1 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Other4 trials
Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors
Actively Recruiting
PI: Pengming Sun, PhD (Fujian Maternity and Child Health Hospital, Affili) · Sites: Fuzhou, Fujian; Fuzhou, Fujian +7 more
View on ClinicalTrials.gov ↗I'm interested →
YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs.
Actively Recruiting
PI: Francesca Spada, MD (Istituto Europeo di Oncologia) · Sites: Milan · Age: 18–39 yrs
View on ClinicalTrials.gov ↗I'm interested →
Risk Factors for Neuroendocrine Neoplasms
Actively Recruiting
PI: Jacqueline Müller-Nordhorn (Bavarian Cancer Registry, Bavarian Health and Food) · Sites: Nuremberg, Bavaria
View on ClinicalTrials.gov ↗I'm interested →
Observational Study on GEP-and Pulm-NET Treated at FPG
Actively Recruiting
PI: Giovanni Schinzari (Fondazione Policlinico Universitario A. Gemelli, I) · Sites: Rome · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →

Specialists

Showing 25 of 29View all specialists →
GD
Georgios Dimitriadis
London, United Kingdom of Great Britain and Northern Irela
Specialist

Rare Disease Specialist

PI on 1 active trial4 Neuroendocrine neoplasm publications
AM
Aaron R Mangold
SCOTTSDALE, AZ
Specialist
PI on 2 active trials
AM
Alberto S. Pappo, MD
MEMPHIS, TN
Specialist
PI on 4 active trials1 Neuroendocrine neoplasm publication
RM
Ramaprasad Srinivasan, M.D.
BETHESDA, MD
Specialist
PI on 6 active trials
UD
Urielle Desalbres
Specialist
PI on 21 active trials1 Neuroendocrine neoplasm publication
LM
Lillian Siu, MD
Specialist
PI on 13 active trials
JX
Jianming Xu
Specialist
PI on 2 active trials
PM
Prashant Chittiboina, M.D.
Bethesda, Maryland
Specialist

Rare Disease Specialist

PI on 7 active trials
LS
Lin Shen
Specialist
PI on 7 active trials110 Neuroendocrine neoplasm publications
RA
Rodabe N Amaria
HOUSTON, TX
Specialist
PI on 3 active trials1 Neuroendocrine neoplasm publication
PF
Paul Lorigan, MBBCH, FRCP
Specialist
PI on 1 active trial
FM
F. Stephen Hodi, MD
Specialist
PI on 5 active trials
XP
Xianjun Yu, MD, PhD
Specialist
PI on 6 active trials
LP
Laura C Hernández Ramírez, MD, PhD
Mexico City, Mexico City
Specialist

Rare Disease Specialist

PI on 1 active trial
PJ
Paul J Jannetto
Specialist
PI on 1 active trial
SD
Shengjie Guo, doctor
Guangzhou, Guangdong
Specialist

Rare Disease Specialist

PI on 2 active trials
PM
Paul Chapman, MD
Specialist
PI on 4 active trials
JM
John Kirkwood, MD
Specialist
PI on 3 active trials
KL
Kenneth Linden
ROSEBURG, OR
Specialist
PI on 1 active trial4 Neuroendocrine neoplasm publications
SM
Stergios Moschos, MD
Chapel Hill, North Carolina
Specialist

Rare Disease Specialist

PI on 3 active trials
EM
Esben Carlsen, MD
Specialist
PI on 1 active trial
LP
Lorigan, Prof
Specialist
PI on 1 active trial
LP
Lisbet R Hölmich, MD, DMSc, Clinical Professor
Specialist
PI on 1 active trial
JP
Jan Grimm, MD, PhD
NEW YORK, NY
Specialist
PI on 1 active trial
PP
Prof. C.J.A. Punt, MD, PhD
Specialist
PI on 3 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center ↗

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center ↗

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program ↗

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site ↗

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site ↗

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site ↗

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine ↗

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program ↗

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Neuroendocrine neoplasm.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Neuroendocrine neoplasmForum →

No community posts yet. Be the first to share your experience with Neuroendocrine neoplasm.

Start the conversation →

Latest news about Neuroendocrine neoplasm

Disease timeline:

New recruiting trial: PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours

A new clinical trial is recruiting patients for Neuroendocrine neoplasm

New recruiting trial: Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment

A new clinical trial is recruiting patients for Neuroendocrine neoplasm

New recruiting trial: R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

A new clinical trial is recruiting patients for Neuroendocrine neoplasm

New recruiting trial: Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

A new clinical trial is recruiting patients for Neuroendocrine neoplasm

New recruiting trial: Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients

A new clinical trial is recruiting patients for Neuroendocrine neoplasm

New recruiting trial: Clinical Trial of Telenursing for Monitoring Supportive Care Needs in Patients With Lung Cancer and Melanoma Candidates for the First Prescription of Targeted Therapies

A new clinical trial is recruiting patients for Neuroendocrine neoplasm

New recruiting trial: NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial

A new clinical trial is recruiting patients for Neuroendocrine neoplasm

New recruiting trial: Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake

A new clinical trial is recruiting patients for Neuroendocrine neoplasm

New recruiting trial: WoW - Single- vs Two-staged Excisions of Thin Melanoma

A new clinical trial is recruiting patients for Neuroendocrine neoplasm

New recruiting trial: HX009+ IN10018 with or Without Standard Chemotherapy for Advanced Solid Tumours

A new clinical trial is recruiting patients for Neuroendocrine neoplasm

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Neuroendocrine neoplasm

Are there clinical trials for Neuroendocrine neoplasm?

Yes — 12 recruiting clinical trials are currently listed for Neuroendocrine neoplasm on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Neuroendocrine neoplasm?

25 specialists and care centers treating Neuroendocrine neoplasm are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.